Literature DB >> 9922383

Role of CFTR in airway disease.

J M Pilewski1, R A Frizzell.   

Abstract

Role of CFTR in Airway Disease. Physiol. Rev. 79, Suppl.: S215-S255, 1999. - Cystic fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), which accounts for the cAMP-regulated chloride conductance of airway epithelial cells. Lung disease is the chief cause of morbidity and mortality in CF patients. This review focuses on mechanisms whereby the deletion or impairment of CFTR chloride channel function produces lung disease. It examines the major themes of the channel hypothesis of CF, which involve impaired regulation of airway surface fluid volume or composition. Available evidence indicates that the effect of CFTR deletion alters physiological functions of both surface and submucosal gland epithelia. At the airway surface, deletion of CFTR causes hyperabsorption of sodium chloride and a reduction in the periciliary salt and water content, which impairs mucociliary clearance. In submucosal glands, loss of CFTR-mediated salt and water secretion compromises the clearance of mucins and a variety of defense substances onto the airway surface. Impaired mucociliary clearance, together with CFTR-related changes in the airway surface microenvironment, leads to a progressive cycle of infection, inflammation, and declining lung function. Here, we provide the details of this pathophysiological cascade in the hope that its understanding will promote the development of new therapies for CF.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9922383     DOI: 10.1152/physrev.1999.79.1.S215

Source DB:  PubMed          Journal:  Physiol Rev        ISSN: 0031-9333            Impact factor:   37.312


  136 in total

1.  Characterization of basolateral K+ channels underlying anion secretion in the human airway cell line Calu-3.

Authors:  Elizabeth A Cowley; Paul Linsdell
Journal:  J Physiol       Date:  2002-02-01       Impact factor: 5.182

2.  Noninvasive in vivo fluorescence measurement of airway-surface liquid depth, salt concentration, and pH.

Authors:  S Jayaraman; Y Song; L Vetrivel; L Shankar; A S Verkman
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

3.  Alternative treatment for secretory diarrhea revealed in a new class of CFTR inhibitors.

Authors:  Qais Al-Awqati
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 4.  Regulation of the epithelial sodium channel by accessory proteins.

Authors:  Kelly Gormley; Yanbin Dong; Giuseppe A Sagnella
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

5.  Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion.

Authors:  Tonghui Ma; Jay R Thiagarajah; Hong Yang; Nitin D Sonawane; Chiara Folli; Luis J V Galietta; A S Verkman
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

6.  Sequence-specific resonance assignments of ICln, an ion channel cloned from epithelial cells.

Authors:  Andreas Schedlbauer; Georg Kontaxis; Matthias König; Johannes Fürst; Martin Jakab; Markus Ritter; Lisa Garavaglia; Guido Bottà; Giuliano Meyer; Markus Paulmichl; Robert Konrat
Journal:  J Biomol NMR       Date:  2003-12       Impact factor: 2.835

7.  Cystic fibrosis presenting with corneal perforation and crystalline lens extrusion.

Authors:  Danielle S Hall; Saurabh Goyal
Journal:  J R Soc Med       Date:  2010-07       Impact factor: 5.344

8.  Cross-linking of ΔF508-CFTR promotes its trafficking to the plasma membrane.

Authors:  Karen Bernard; Kevin L Kirk
Journal:  Channels (Austin)       Date:  2010-07-23       Impact factor: 2.581

9.  A posttranslational modification code for CFTR maturation is altered in cystic fibrosis.

Authors:  Sandra Pankow; Casimir Bamberger; John R Yates
Journal:  Sci Signal       Date:  2019-01-01       Impact factor: 8.192

10.  CFTR fails to inhibit the epithelial sodium channel ENaC expressed in Xenopus laevis oocytes.

Authors:  G Nagel; P Barbry; H Chabot; E Brochiero; K Hartung; R Grygorczyk
Journal:  J Physiol       Date:  2005-03-03       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.